

# Update to Executive Officer Notice of interim change to Extemporaneous Preparations Policy for Anti-infectives

May 31, 2022

Effective April 16, 2021, the Executive Officer issued an interim change to the Extemporaneous Preparations Policy (EPP), pursuant to subsection 17(2) of the *Ontario Drug Benefit Act*. The purpose of the interim change was to facilitate publicly funded access to select injectable anti-infectives for Ontario Drug Benefit (ODB) Program recipients who require access to selected injectable anti-infective therapy at home.

Prior to the [interim change](#), the EPP stipulated that an extemporaneous preparation for injectable administration that contains an anti-infective injectable drug product with a Notice of Compliance issued after September 3, 2003, is only eligible for ODB Program coverage if the anti-infective injectable drug product is an ODB benefit listed on the Formulary or approved for a specific recipient under the Exceptional Access Program (EAP). The interim change to the EPP removed the requirement for EAP authorization for select anti-infective drug products (see list below) when the drug is being administered to an ODB Program recipient for use at home for a duration of up to 12 weeks following the recipient's discharge from a hospital.

**Effective the date of this notice, the interim change has been updated to apply to any ODB Program recipient who has been prescribed select anti-infectives (see list below) for use at home for a duration of up to 12 weeks, regardless of whether the recipient has been recently discharged from a hospital.**

Prescribers who require one of the below listed injectable drug products will be granted an exemption from the requirement for EAP authorization when the drug is being administered to an ODB Program recipient for use at home for a duration of up to 12 weeks. Use beyond 12 weeks is excluded from this interim change and will require EAP authorization for continued use.

- Acyclovir
- Amikacin
- Amphotericin (Fungizone and generics only)
- Ampicillin
- Azithromycin
- Cefazolin
- Caspofungin
- Cefotaxime
- Cefoxitin
- Ceftazidime
- Cefuroxime
- Ciprofloxacin
- Clindamycin
- Cloxacillin
- Ertapenem
- Erythromycin
- Fluconazole
- Gentamicin
- Imipenem/Cilastatin
- Levofloxacin
- Meropenem
- Metronidazole
- Moxifloxacin
- Penicillin G
- Piperacillin/Tazobactam
- Vancomycin

The EPP can be found in section 6.1 of the Ontario Drug Programs Reference Manual at the following URL:

[https://health.gov.on.ca/en/pro/programs/drugs/resources/odp\\_reference\\_manual.pdf](https://health.gov.on.ca/en/pro/programs/drugs/resources/odp_reference_manual.pdf)

A searchable list that includes drugs that are authorized through the Exceptional Access Program can be found at the following URL:

<https://www.ontario.ca/page/check-medication-coverage/>

For additional questions, you may contact one of the following:

**For pharmacies:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

**For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282

**EAP questions or status of requests:**

E-mail: [EAPFeedback.MOH@ontario.ca](mailto:EAPFeedback.MOH@ontario.ca)

Phone: 416-327-8109 or 1-866-811-9893

Fax: 416-327-7526 or 1-866-811-9908